Clinical Trials Logo

Lymphoma, Large B-Cell, Diffuse clinical trials

View clinical trials related to Lymphoma, Large B-Cell, Diffuse.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT05733650 Approved for marketing - Clinical trials for Large B-cell Lymphoma

Expanded Access Program for Epcoritamab

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this program is to provide investigational epcoritamab, an antibody also known as GEN3013 (DuoBody-CD3xCD20), in an expanded access setting for eligible patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) who have a high unmet medical need with no other treatment options. It is a requirement that patients do not qualify for an ongoing epcoritamab clinical program or are unable to participate due to logistical reasons. Access to investigational epcoritamab can be requested by contacting preapprovalaccessprograms@genmab.com.

NCT ID: NCT03153462 Approved for marketing - Clinical trials for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Axicabtagene Ciloleucel Expanded Access Study

ZUMA-9
Start date: n/a
Phase:
Study type: Expanded Access

A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma. Subjects who received an infusion of axicabtagene ciloleucel will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968